This site is intended for
US
Healthcare Professionals only.

For Patients
 

Clinical Trials

Committed to Immuno-Oncology research

The Bristol-Myers Squibb Immuno-Oncology (I-O) portfolio consists of novel agents in development that are designed to target various immune mechanisms that may enhance antitumor immune response. We are investigating the potential of I-O, including combinations of I-O agents, in a wide range of cancers with the hope of optimizing clinical outcomes.

The Bristol-Myers Squibb Study Connect website provides information regarding new and ongoing clinical trials.

See what's new

Immune Pathways

See where our I-O research into immune pathways is heading

Learn more

I-O Biomarkers

Read about I-O biomarkers we're currently investigating

Learn more